Honors & Awards


  • Predoctoral Fellowship, Ford Foundation (2023-2026)

Education & Certifications


  • B.S., SUNY University at Buffalo, Bioinformatics and Computational Biology (2020)

All Publications


  • A single-cell atlas of human neutrophils reveals neutrophil heterogeneity across health and disease. Nature immunology Zheng, H., Maestri, E., Moore, A. R., Ganesan, A., Enriquez, J., Durán, V., Einav, S., van der Poll, T., Bouma, H. R., Atreya, M. R., Efron, P. A., Moldawer, L. L., Sevransky, J., Wright, D. W., Martin-Loeches, I., Karvunidis, T., Hinson, J., Hager, D. N., Rothman, R. E., Giamarellos-Bourboulis, E. J., Sweeney, T. E., Rogers, A. J., Gombar, S., Maddali, M. V., Chen, J. H., Shah, N., Khatri, P. 2026

    Abstract

    Neutrophils, the most abundant leukocytes in human blood, have multifaceted roles in health and disease. Here we assembled a single-cell atlas of human neutrophils (SCAHN) by integrating transcriptome data from 1 million human neutrophils from 781 samples and 43 independent datasets. Using SCAHN, we identified multiple neutrophil subsets with distinct functions across tissues and robust changes in gene expression and subset proportions in infection, cancer, immune suppression and sex differences at single-cell resolution. Cross-species reference mapping of mouse and nonhuman primate neutrophils onto SCAHN revealed both conserved and species-specific features. Using 17,023 bulk blood transcriptome profiles from 40 datasets, we found that neutrophil-specific signatures predicted mortality in acutely ill patients at presentation, were associated with cancer diagnosis and survival, and correlated with metabolic dysfunction and long-term all-cause mortality. Our study highlights how neutrophil biology can improve immune risk stratification and develop effective diagnostic and therapeutic strategies.

    View details for DOI 10.1038/s41590-026-02671-8

    View details for PubMedID 42907583

    View details for PubMedCentralID 7615267

  • Zanubrutinib monotherapy for IgG4-related head and neck disease. Annals of the rheumatic diseases Baker, M. C., Gawde, S., Horomanski, A., Fairchild, R. M., Liu, Y., Mikelov, A., Sun, Y., Vitale, M. R., Maestri, E., Held, F., Deluna, M., Park, W. G., Siddiqi, H., Taylor, L., Bopardikar, S., Khalighi, M., Franc, B. L., Penta, M., Boyd, S. D., Khatri, P., Zhu, H., Pham, N., Guja, K. E., Lanz, T. V. 2026

    Abstract

    Immunoglobulin (Ig) G4-related disease (IgG4-RD) is commonly treated with glucocorticoids and B-cell depletion, but cumulative toxicity and relapse underscore the need for alternative approaches. We evaluated the efficacy, safety, and immunological effects of Bruton's tyrosine kinase (BTK) inhibition with zanubrutinib in active IgG4-RD.In this phase 2, open-label, proof-of-concept trial, 10 participants with lacrimal and submandibular gland IgG4-RD received zanubrutinib 80 mg twice daily for up to 24 weeks without glucocorticoid induction or background immunosuppression. The primary endpoint was change in lacrimal and submandibular gland volume at week 24 by blinded fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (evaluable n = 8). Secondary endpoints included metabolic imaging parameters, clinical disease activity, serologic biomarkers, and safety. Single-cell RNA sequencing with immune repertoire profiling was performed to define cellular mechanisms.At week 24, mean gland volume decreased by 46.7% (lacrimal) and 29.9% (submandibular) (both P = .008), with concordant reductions in total lesion glycolysis (-91.6 g; P = .05) and total metabolic lesion volume (-20.7 cm³; P = .05). Clinical disease activity improved (IgG4-RD Responder Index -6.0 points; P = .01), alongside reductions in serum IgG4 (-417 mg/dL; P = .008) and circulating plasmablasts. Imaging and serologic changes were strongly correlated. Single-cell analyses demonstrated treatment-associated modulation of B-cell transcriptional programmes, reductions in IgG4-skewed plasmablasts, and attenuation of cytotoxic CD4⁺ T cells. Adverse events were predominantly mild; 1 serious event (COVID-19) occurred off treatment.Zanubrutinib monotherapy produced substantial imaging-defined and clinical improvements in active glandular IgG4-RD without glucocorticoid induction. BTK inhibition was associated with modulation of B-cell differentiation states and downstream immune programmes, supporting its development as a steroid-sparing, non-B-cell-depleting therapeutic strategy.

    View details for DOI 10.1016/j.ard.2026.06.020

    View details for PubMedID 42448495

  • Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial. Open forum infectious diseases Jagannathan, P., Hedlin, H., Liang, J. W., Shaw, B., Maestri, E., Lin, M., Utz, P. J., Singh, U., Geng, L. N., Bonilla, H. 2025; 12 (10): ofaf634

    Abstract

    Long COVID is a heterogeneous post-infectious condition. Although patient-reported outcome (PRO) measures for diagnosis or therapeutic monitoring have been adapted from related complex chronic illnesses, no PRO has been validated specifically in Long COVID. The STOP-PASC randomized, placebo-controlled trial of nirmatrelvir/ritonavir (NMV/r) in adults with Long COVID showed no overall treatment effect. This exploratory analysis aimed to identify distinct symptom trajectories and clinical characteristics associated with improvement or worsening over time.We performed latent class trajectory modeling (LCTM) on PRO measures-including the Patient Global Impression of Severity (PGIS), Patient Global Impression of Change (PGIC), PROMIS domains, and core symptoms-among 155 randomized participants. Participants were followed for 15 weeks with serial symptom assessments. Trajectory groups were identified using Bayesian Information Criteria and characterized using descriptive statistics and absolute standardized differences.LCTM revealed heterogeneity in symptom trajectories. Two groups emerged for PGIS (improving n = 17, persistent/severe n = 136) and PGIC (improving n = 130; worsening n = 22). PROMIS-Physical Function modeling identified four groups (improving, normal/mild, moderate, and severe), fatigue core symptom modeling identified three (improving; moderate; severe). Worsening groups had higher proportions of NMV/r-treated participants and greater prevalence of cardiovascular symptoms and low-dose naltrexone use. Improving groups had shorter time since infection and higher baseline physical function. No subgroup showed a clear benefit from NMV/r.Distinct PRO trajectories reflect the clinical heterogeneity of Long COVID. NMV/r showed no clear benefit across subgroups. These findings emphasize the need for validated, Long COVID-specific PRO instruments and targeted therapeutic trials tailored to Long COVID subtypes.

    View details for DOI 10.1093/ofid/ofaf634

    View details for PubMedID 41164784

    View details for PubMedCentralID PMC12560753

  • Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology (Baltimore, Md.) Hsu, C. L., Wang, L., Maestri, E., Jacob, A. R., Do, W. L., Mayo, S., Bosques-Padilla, F., Verna, E. C., Abraldes, J. G., Brown, R. S., Vargas, V., Altamirano, J., Caballería, J., Shawcross, D. L., Louvet, A., Lucey, M. R., Mathurin, P., Garcia-Tsao, G., Stärkel, P., Bataller, R., Investigators, A., Wang, X. W., Schnabl, B. 2024

    Abstract

    Alcohol-associated hepatitis (AH) is associated with very high mortality despite abstinence from alcohol; up to 40% of patients die within 6 months of diagnosis. Patients with AH are especially prone to infections, which can lead to multiorgan dysfunction and poorer prognosis.We performed comprehensive serological profiling of the viral and bacterial infection history of 36 healthy controls, 48 patients with alcohol use disorder, and 224 patients with AH from 2 multicenter observational studies. We used systematic viral and bacterial epitope scanning by VirScan, a phage-display immunoprecipitation and sequencing technology that detects the peptides recognized by antibodies in patient sera, to comprehensively analyze antiviral and antibacterial antibodies and identify serologic biomarkers to predict patient outcomes. We found significant differences in the serological profiles of the 3 populations. The number of serum antibody epitopes in patients with alcohol use disorder during abstinence was increased compared with during active alcohol use. A decreased number and diversity of viral and bacterial antibody targets were detected in the sera of patients with AH, particularly those with a higher Child-Pugh score. In patients with AH, a decrease in the serum antiviral, but not antibacterial, antibody repertoire was associated with decompensation and mortality. Ninety-day mortality in AH could be predicted using a serum viral epitope signature.Abstinence from alcohol is associated with a significant increase in serum viral and bacterial antibody response. Decreased serum antiviral antibody repertoire is predictive of decompensation of liver disease and mortality in patients with AH.

    View details for DOI 10.1097/HEP.0000000000001046

    View details for PubMedID 39325984

  • Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatology (Baltimore, Md.) Maestri, E., Kedei, N., Khatib, S., Forgues, M., Ylaya, K., Hewitt, S. M., Wang, L., Chaisaingmongkol, J., Ruchirawat, M., Ma, L., Wang, X. W. 2024; 79 (4): 768-779

    Abstract

    The fitness and viability of a tumor ecosystem are influenced by the spatial organization of its cells. We aimed to study the structure, architecture, and cell-cell dynamics of the heterogeneous liver cancer tumor microenvironment using spatially resolved multiplexed imaging.We performed co-detection by indexing multiplexed immunofluorescence imaging on 68 HCC biopsies from Thai patients [(Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC)] as a discovery cohort, and then validated the results in an additional 190 HCC biopsies from Chinese patients [Liver Cancer Institute (LCI)]. We segmented and annotated 117,270 and 465,632 cells from the TIGER-LC and LCI cohorts, respectively. We observed 4 patient groups of TIGER-LC (IC1, IC2, IC3, and IC4) with distinct tumor-immune cellular interaction patterns. In addition, patients from IC2 and IC4 had much better overall survival than those from IC1 and IC3. Noticeably, tumor and CD8 + T-cell interactions were strongly enriched in IC2, the group with the best patient outcomes. The close proximity between the tumor and CD8 + T cells was a strong predictor of patient outcome in both the TIGER-LC and the LCI cohorts. Bulk transcriptomic data from 51 of the 68 HCC cases were used to determine tumor-specific gene expression features of our classified subtypes. Moreover, we observed that the presence of immune spatial neighborhoods in HCC as a measure of overall immune infiltration is linked to better patient prognosis.Highly multiplexed imaging analysis of liver cancer reveals tumor-immune cellular heterogeneity within spatial contexts, such as tumor and CD8 + T-cell interactions, which may predict patient survival.

    View details for DOI 10.1097/HEP.0000000000000600

    View details for PubMedID 37725716

    View details for PubMedCentralID PMC10948323

  • A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases JCI INSIGHT Boyles, J. S., Sadowski, D., Potter, S., Vukojicic, A., Parker, J., Chang, W. Y., Ma, Y. L., Chambers, M. G., Nelson, J., Barmettler, B., Smith, E. M., Kersjes, K., Himes, E. R., Lin, C., Lucchesi, J., Brahmbhatt, J., Sina, R., Martin, J. A., Maestri, E., Wiethoff, C. M., Dyas, G. L., Linnik, M. D., Na, S., Witcher, D. R., Budelsky, A., Rubtsova, K. 2023; 8 (13)

    Abstract

    B cells contribute to multiple aspects of autoimmune disorders, and B cell-targeting therapies, including B cell depletion, have been proven to be efficacious in treatment of multiple autoimmune diseases. However, the development of novel therapies targeting B cells with higher efficacy and a nondepleting mechanism of action is highly desirable. Here we describe a nondepleting, high-affinity anti-human CD19 antibody LY3541860 that exhibits potent B cell inhibitory activities. LY3541860 inhibits B cell activation, proliferation, and differentiation of primary human B cells with high potency. LY3541860 also inhibits human B cell activities in vivo in humanized mice. Similarly, our potent anti-mCD19 antibody also demonstrates improved efficacy over CD20 B cell depletion therapy in multiple B cell-dependent autoimmune disease models. Our data indicate that anti-CD19 antibody is a highly potent B cell inhibitor that may have potential to demonstrate improved efficacy over currently available B cell-targeting therapies in treatment of autoimmune conditions without causing B cell depletion.

    View details for DOI 10.1172/jci.insight.166137

    View details for Web of Science ID 001024358200001

    View details for PubMedID 37427592

    View details for PubMedCentralID PMC10371335